Основная статистика
| LEI | 54930027RQTU9CHLKL88 |
| CIK | 1492674 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to T2 Biosystems, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 T2 BIOSYSTEMS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36571 20-4827488 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 1, 2025 |
SEC File Number: 001-31326 CUSIP Number: 29014R103 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 T2 BIOSYSTEMS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36571 20-4827488 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 14, 2025 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 T2 BIOSYSTEMS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36571 20-4827488 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| January 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| January 7, 2025 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results Achieved record fourth quarter and full-year 2024 sepsis product revenues LEXINGTON, Mass., January 7, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced prel |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 9, 2024 |
Exhibit 99.1 T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream LEXINGTON, Mass., December 9, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ: |
|
| November 20, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy S |
|
| November 15, 2024 |
EX-99.2 Exhibit 99.2 Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products. Forward-looking statements are based on estimates and assumpti |
|
| November 15, 2024 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces Third Quarter 2024 Financial Results Achieved 34% quarterly revenue growth compared to the prior year period LEXINGTON, Mass., November 14, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational result |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| November 14, 2024 |
Exhibit 10.3 AMENDMENT TO RETENTION BONUS LETTER AGREEMENT This Amendment to Retention Bonus Letter Agreement is entered into as of November 13, 2024, by and between T2 Biosystems, Inc., a Delaware corporation having its principal place of business at 101 Hartwell Avenue, Lexington, Massachusetts 02421 USA (“T2 Bio”) and Michael Gibbs (“Employee”). Capitalized terms used herein without definition |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Bi |
|
| November 14, 2024 |
TTOO / T2 Biosystems, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-ttoo093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89853L302 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 14, 2024 |
Exhibit 10.1 AMENDMENT NO. 7 TO COMMERCIAL LEASE BETWEEN COLUMBUS DAY REALTY, INC. AND T2 BIOSYSTEMS, INC. This Amendment No. 7 is to a Commercial Lease dated May 6, 2013, by and between Columbus Day Realty, Inc. (LESSOR), and T2 Biosystems, Inc. (LESSEE), which lease relates to the premises at 231 Andover Street, Wilmington, Massachusetts. WHEREAS, the Commercial Lease is dated May 6, 2013; WHERE |
|
| November 14, 2024 |
Exhibit 10.2 AMENDMENT TO RETENTION BONUS LETTER AGREEMENT This Amendment to Retention Bonus Letter Agreement is entered into as of November 13, 2024, by and between T2 Biosystems, Inc., a Delaware corporation having its principal place of business at 101 Hartwell Avenue, Lexington, Massachusetts 02421 USA (“T2 Bio”) and John Sprague (“Employee”). Capitalized terms used herein without definition s |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy S |
|
| November 6, 2024 |
EX-99.1 2 ex991tosc13g10871ttoo110624.htm Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated November 6, 2024 with respect to the Common Stock, par value $0.001 per share, of T2 Biosystems, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the unders |
|
| November 6, 2024 |
TTOO / T2 Biosystems, Inc. / Safier Jacob Passive Investment SC 13G 1 sc13g10871ttoo11062024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securi |
|
| November 6, 2024 |
TTOO / T2 Biosystems, Inc. / JSAF Holdings, LLC Passive Investment SC 13G 1 sc13g10871ttoo11062024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securi |
|
| November 6, 2024 |
EX-99.1 2 ex991tosc13g10871ttoo110624.htm Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated November 6, 2024 with respect to the Common Stock, par value $0.001 per share, of T2 Biosystems, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the unders |
|
| October 16, 2024 |
Exhibit 99.1 T2 Biosystems Business Update October 10, 2024 Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products. Forward-looking stateme |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 7, 2024 |
Exhibit 99.1 T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results Achieved 35% increase in total revenue compared to prior year period LEXINGTON, Mass., October 7, 2024 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational r |
|
| October 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 20, 2024 |
EX-99.1 Exhibit 99.1 T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union LEXINGTON, Mass., September 20, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended ag |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission |
|
| September 16, 2024 |
Exhibit 99.1 T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients Expands available market to include over 200 children’s hospitals in the United States LEXINGTON, Mass., September 16, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today annou |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| September 9, 2024 |
EX-99.1 Exhibit 99.1 T2 Biosystems Provides Updates on its New Product Development Pipeline Progress Company plans to launch multiple direct-from-blood diagnostics over the next 15 months for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris LEXINGTON, Mass., September 9, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the |
|
| August 23, 2024 |
Up to $13,390,000 Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-280922 PROSPECTUS SUPPLEMENT (To Sales Agreement Prospectus dated July 29, 2024) Up to $13,390,000 Common Stock This Prospectus Supplement supplements the sales agreement prospectus, dated July 29, 2024 (the “ATM Prospectus”), relating to the offer and sale of shares of our common stock, $0.001 par value per share (“common stock”), having an |
|
| August 15, 2024 |
TTOO / T2 Biosystems, Inc. / New Dimensions Trading Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89853L302 (CUSIP Number) Apri |
|
| August 15, 2024 |
TTOO / T2 Biosystems, Inc. / Safier Jacob Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89853L302 (CUSIP Number) Apri |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Biosyst |
|
| July 29, 2024 |
Exhibit 99.1 T2 Biosystems Announces Second Quarter 2024 Financial Results Achieved record quarterly and first half sepsis test revenue, representing growth of 27% and 25% respectively compared to the prior year periods LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resi |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| July 29, 2024 |
Exhibit 99.2 T2 Biosystems 2Q 2024 July 29, 2024 KLG Comments: 7.29.24 Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products. Forward-look |
|
| July 26, 2024 |
T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, Massachusetts 02421 T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, Massachusetts 02421 July 26, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: T2 Biosystems, Inc. Registration Statement on Form S-3 Filed July 19, 2024 File No. 333-280922 To whom it may concern: Pursuant to Rule 461(a) under the Securities Act |
|
| July 19, 2024 |
Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT July 19, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: T2 Biosystems, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agr |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| July 19, 2024 |
Exhibit 4.2 T2 BIOSYSTEMS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page Article I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 Article II. THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment of Te |
|
| July 19, 2024 |
As filed with the Securities and Exchange Commission on July 19, 2024. Table of Contents As filed with the Securities and Exchange Commission on July 19, 2024. |
|
| July 19, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Registration Statement on Form S-3 (Form Type) T2 Biosystems, Inc. |
|
| May 31, 2024 |
T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, Massachusetts 02421 T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, Massachusetts 02421 May 31, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: T2 Biosystems, Inc. Registration Statement on Form S-3 Filed May 28, 2024 File No. 333-279740 To whom it may concern: Pursuant to Rule 461(a) under the Securities Act of |
|
| May 28, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-1 (Form Type) T2 Biosystems, Inc. |
|
| May 28, 2024 |
As filed with the Securities and Exchange Commission on May 24, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 24, 2024 Registration No. |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 20, 2024 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 14, 2024, between T2 Biosystems, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| May 20, 2024 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| May 20, 2024 |
EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| May 20, 2024 |
EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| May 20, 2024 |
Exhibit 10.2 EXHIBIT B REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 14, 2024, by and between T2 Biosystems, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securit |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 20, 2024 |
EX-4.4 Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| May 14, 2024 |
T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, MA 02421 T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, MA 02421 May 14, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: T2 Biosystems, Inc. Registration Statement on Form S-1 File No. 333-278866 Ladies and Gentlemen: T2 Biosystems, Inc. (the “Company”) hereby respectfully requests pursuant to Rule 477 of the Securitie |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 13, 2024 |
TTOO / T2 Biosystems, Inc. / CR Group L.P. - SC 13D/A Activist Investment SC 13D/A 1 d838783dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89853L302 (CUSIP Number) Andrei Dorenbaum c/o CR Group L.P. 1000 Main Street, Suite 2500 Houston, TX 77002 |
|
| May 8, 2024 |
FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 7, 2024 |
TTOO / T2 Biosystems, Inc. / CR Group L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89853L302 (CUSIP Number) Andrei Dorenbaum c/o CR Group L.P. 1000 Main Street, Suite 2500 Houston, TX 77002 (703) 209-7350 (Name, Address |
|
| May 7, 2024 |
Strengthens balance sheet by reducing total debt by approximately 80% over the past year T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity Strengthens balance sheet by reducing total debt by approximately 80% over the past year Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. |
|
| May 7, 2024 |
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor T2 Biosystems Announces Commercial Expansion Through Middle East Distributor Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 Registration No. |
|
| May 6, 2024 |
As filed with the Securities and Exchange Commission on May 6, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 6, 2024 Registration No. |
|
| May 6, 2024 |
Power of Attorney (included on the signature page) S-1/A Table of Contents As filed with the Securities and Exchange Commission on May 6, 2024 Registration No. |
|
| May 6, 2024 |
EX-10.65 Exhibit 10.65 SERIES B-2 WARRANT TO PURCHASE SHARES OF COMMON STOCK T2 BIOSYSTEMS, INC. Warrant Shares: Original Issuance Date: [ ], 2024 Initial Exercise Date: [ ], 2024 THIS SERIES B-2 WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the |
|
| May 6, 2024 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made as of May 3, 2024, by and among CRG Partners III L.P., CRG Partners III—Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund “B” (Cayman) L.P. (together, “CRG” or the “Purchasers |
|
| May 6, 2024 |
Exhibit 99.1 T2 Biosystems Announces First Quarter 2024 Financial Results Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period LEXINGTON, Mass., May 6, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today a |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 6, 2024 |
EX-10.2 Exhibit 10.2 CONSENT AND AMENDMENT NO. 11 TO TERM LOAN AGREEMENT THIS CONSENT AND AMENDMENT NO. 11 TO TERM LOAN AGREEMENT, dated as of May 3, 2024 (this “Amendment”), is made among T2 BIOSYSTEMS, INC., a Delaware corporation (“Borrower”), the other Obligors party hereto, CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, “Administrative Agent”) and the len |
|
| May 6, 2024 |
EX-10.64 Exhibit 10.64 SERIES B-1 WARRANT TO PURCHASE SHARES OF COMMON STOCK T2 BIOSYSTEMS, INC. Warrant Shares: Original Issuance Date: [ ], 2024 Initial Exercise Date: [ ], 2024 THIS SERIES B-1 WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Biosys |
|
| May 6, 2024 |
Form of Securities Purchase Agreement EX-10.63 Exhibit 10.63 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May [ ], 2024, between T2 Biosystems, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| May 6, 2024 |
Form of Placement Agency Agreement EX-1.1 Exhibit 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 May [ ], 2024 T2 Biosystems, Inc. Attention: John Sperzel 101 Hartwell Avenue Lexington, MA 02421 Re: Placement Agency Agreement Dear Mr. Sperzel: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”), as sole |
|
| May 6, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-1 (Form Type) T2 Biosystems, Inc. |
|
| May 6, 2024 |
EX-10.66 Exhibit 10.66 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK T2 BIOSYSTEMS, INC. Warrant Shares: Issue Date: [ ], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any tim |
|
| May 6, 2024 |
EX-99.2 Exhibit 99.2 T2 Biosystems 1Q 2024 May 6, 2024 Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products. Forward-looking statements a |
|
| April 22, 2024 |
As filed with the Securities and Exchange Commission on April 22, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 22, 2024 Registration No. |
|
| April 22, 2024 |
Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-1 (Form Type) T2 Biosystems, Inc. |
|
| April 19, 2024 |
TTOO / T2 Biosystems, Inc. / CR Group L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89853L302 (CUSIP Number) Andrei Dorenbaum c/o CR Group L.P. 1000 Main Street, Suite 2500 Houston, TX 77002 (703) 209-7350 (Name, Address an |
|
| April 19, 2024 |
EX-99.1 2 d830497dex991.htm EX-99.1 CUSIP No. 89853L302 Page 13 of 13 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of T2 Biosystems, Inc. and further agree th |
|
| April 18, 2024 |
Exhibit 3.1 T2 BIOSYSTEMS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW T2 BIOSYSTEMS, INC., Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in acco |
|
| April 18, 2024 |
Exhibit 10.1 Execution Version CONSENT AND AMENDMENT NO. 10 TO TERM LOAN AGREEMENT THIS CONSENT AND AMENDMENT NO. 10 TO TERM LOAN AGREEMENT, dated as of April 12, 2024 (this “Consent”) is made among T2 BIOSYSTEMS, INC., a Delaware corporation (“Borrower”), the other Obligors party hereto, CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, “Administrative Agent”) a |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| April 1, 2024 |
Exhibit 21.1 Subsidiaries of T2 Biosystems, Inc.: Name Jurisdiction of Organization T2 Biosystems Securities Corporation Massachusetts |
|
| April 1, 2024 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT General As of December 31, 2023, T2 Biosystems, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). References herein to “we,” “us,” “our” and the “Company” refer to T2 Biosystems, Inc. and not to any of its subsidi |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36571 T2 Biosystems, In |
|
| April 1, 2024 |
Exhibit 10.61 March 31, 2024 Michael Gibbs Re: Retention Bonus Dear Michael, T2 Biosystems, Inc. (the “Company” or “T2”) is pleased to inform you that you are eligible to earn a special, one-time retention bonus (the “Retention Bonus”) in the total aggregate amount of $80,000, to be paid in two installments of $40,000, pursuant to the terms and conditions set forth in this letter agreement. Subjec |
|
| April 1, 2024 |
T2 Biosystems, Inc. Clawback Policy Exhibit 97.1 T2 BIOSYSTEMS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION T2 Biosystems, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy Thi |
|
| April 1, 2024 |
Exhibit 10.60 March 31, 2024 John Sprague Re: Retention Bonus Dear Michael, T2 Biosystems, Inc. (the “Company” or “T2”) is pleased to inform you that you are eligible to earn a special, one-time retention bonus (the “Retention Bonus”) in the total aggregate amount of $80,000, to be paid in two installments of $40,000, pursuant to the terms and conditions set forth in this letter agreement. Subject |
|
| March 28, 2024 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., th |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| March 20, 2024 |
EX-99.1 Exhibit 99.1 T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024 LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans |
|
| March 20, 2024 |
EX-99.2 Exhibit 99.2 T2 Biosystems Investor Update March 20, 2024 Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products. Forward-looking s |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| March 18, 2024 |
Exhibit 99.1 T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes LEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detecti |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| March 11, 2024 |
TTOO / T2 Biosystems, Inc. / New Dimensions Trading Passive Investment SC 13G 1 sc13g1087100103112024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securit |
|
| March 11, 2024 |
EX-99.1 2 ex991to13g10871001031124.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 11, 2024 with respect to the Common Stock, par value $0.001 per share, of T2 Biosystems, Inc., a Delaware corporation, and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of |
|
| March 11, 2024 |
EX-99.1 2 ex991to13g10871001b031124.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 11, 2024 with respect to the Common Stock, par value $0.001 per share, of T2 Biosystems, Inc., a Delaware corporation, and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of |
|
| March 11, 2024 |
TTOO / T2 Biosystems, Inc. / Safier Jacob Passive Investment SC 13G 1 sc13g10871001b03112024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securi |
|
| March 4, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy S |
|
| February 16, 2024 |
EX-99.1 Exhibit 99.1 T2 Biosystems 4Q 2023 February 15, 2024 Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products. Forward-looking statem |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| February 15, 2024 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 15, 2024 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made as of February 15, 2024, by and among CRG Partners III L.P., CRG Partners III - Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund “B” (Cayman) L.P. (together, “CRG” or the “Pu |
|
| February 15, 2024 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales LEXINGTON, Mass., February 15, 2024 (GLOBE NEWSWIRE)— T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| February 13, 2024 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of T2 Biosystems, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. February 13, 2024 LIND GLOBAL FUND II LP By: Lind Global Partners II LLC |
|
| February 13, 2024 |
US89853L3024 / T2 BIOSYSTEMS INC COM USD0 001 / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89853L302 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorpora |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form. |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Bi |
|
| November 15, 2023 |
Exhibit 10.5 Execution Version AMENDMENT No. 9 TO TERM LOAN AGREEMENT THIS AMENDMENT NO. 9 TO TERM LOAN AGREEMENT, dated as of October 18, 2023 (this “Amendment”) is made among T2 BIOSYSTEMS, INC., a Delaware corporation (“Borrower”), the other Obligors party hereto, CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, “Administrative Agent”) and the lenders listed |
|
| November 15, 2023 |
Exhibit 10.4 T2 BIOSYSTEMS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN (as amended and restated effective October 12, 2023) ARTICLE 1. PURPOSE The purposes of this T2 Biosystems, Inc. 2014 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of T2 Biosystems, Inc., a Delaware corporation (the “Company”), and its Designated Subsi |
|
| November 15, 2023 |
Exhibit 10.3 T2 BIOSYSTEMS, INC. 2014 INCENTIVE AWARD PLAN (as amended and restated effective October 12, 2023) ARTICLE 1. PURPOSE The purpose of the T2 Biosystems, Inc. 2014 Incentive Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of T2 Biosystems, Inc. (the “Company”) by linking the individual interests of the members o |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 25, 2023 |
T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference EX-99.1 Exhibit 99.1 T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference Data demonstrates speed, accuracy, and clinical benefits of the T2Dx Instrument and T2 Biosystems’ sepsis panels, including encouraging early detection data for T2Resistance Panel LEXINGTON, Mass., October 24, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection o |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 17, 2023 |
EX-99.1 Exhibit 99.1 T2 Biosystems 3Q 2023 October 12, 2023 Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products. Forward-looking stateme |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 12, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF T2 BIOSYSTEMS, INC. T2 Biosystems, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: That, the Board of Directors of the Company duly adopted resolutions by unanimous written consent in a |
|
| October 12, 2023 |
T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates EX-99.1 Exhibit 99.1 T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance sheet LEXINGTON, Mass., October 12, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resist |
|
| October 12, 2023 |
T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its EX-99.2 Exhibit 99.2 T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii LEXINGTON, Mass., October 12, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitte |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission |
|
| September 13, 2023 |
T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, MA 02421 T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, MA 02421 September 13, 2023 VIA EDGAR TRANSMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: T2 Biosystems, Inc. Registration Statement on Form S-3 File No. 333-274182 To the addressee set forth above: T2 Biosystems, Inc. (the “Company”) hereby respectfully requests the wi |
|
| September 12, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| September 11, 2023 |
T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, MA 02421 T2 Biosystems, Inc. 101 Hartwell Avenue Lexington, MA 02421 September 11, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: T2 Biosystems, Inc. Registration Statement on Form S-3 File No. 333-274182 To the addressee set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the |
|
| August 24, 2023 |
As filed with the Securities and Exchange Commission on August 24, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 24, 2023 Registration No. |
|
| August 24, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) T2 Biosystems, Inc. |
|
| August 18, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| August 11, 2023 |
EX-99.2 Exhibit 99.2 T2 Biosystems 2Q August 7, 2023 Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products. Forward-looking statements are |
|
| August 11, 2023 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces Second Quarter 2023 Financial Results Received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel orders and received second largest sepsis driven T2Dx® Instrument order LEXINGTON, Mass., August 7, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection |
|
| August 9, 2023 |
T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement EX-99 Exhibit 99.1 T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement LEXINGTON, Mass., August 9, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Biosyst |
|
| July 31, 2023 |
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements EX-99.1 Exhibit 99.1 T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements LEXINGTON, Mass., July 31, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension through Nove |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| July 26, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| July 20, 2023 |
T2 Biosystems Receives FDA Breakthrough Device Designation for EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough De |
|
| July 13, 2023 |
US89853L2034 / T2 Biosystems Inc / CR Group L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89853L203 (CUSIP Number) July 3, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| July 13, 2023 |
EX-99.A CUSIP No. 89853L203 Page 1 4 of 14 EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of T2 Biosystems, Inc. and further agree that this agreement be included |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| July 12, 2023 |
Up to $65,000,000 Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333- 254918 AMENDMENT NO. 1 DATED JULY 12, 2023 To Prospectus Supplement dated April 9, 2021 and Prospectus dated April 9, 2021 Up to $65,000,000 Common Stock This Amendment No. 1 to Prospectus Supplement, or this amendment, amends our prospectus supplement dated April 9, 2021, or the prospectus supplement. This amendment sh |
|
| July 12, 2023 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results Received record quarterly sepsis test panel orders and strengthened balance sheet LEXINGTON, Mass., July 12, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financia |
|
| July 12, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 6, 2023 |
EX-3.1 Exhibit 3.1 T2 BIOSYSTEMS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of T2 BIOSYSTEMS, INC., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors |
|
| July 6, 2023 |
EX-10.1 Exhibit 10.1 Execution Version PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”) is made as of July 5, 2023, by and among CRG Partners III L.P., CRG Partners III - Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. (each, a “Purchaser” and collectively, the “Purchaser |
|
| July 6, 2023 |
EX-3.2 Exhibit 3.2 T2 BIOSYSTEMS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW T2 BIOSYSTEMS, INC., Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, |
|
| July 6, 2023 |
EX-10.2 Exhibit 10.2 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made as of July 3, 2023, by and among CRG Partners III L.P., CRG Partners III - Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund “B” (Cayman) L.P. (together, “CRG” or the “Purchas |
|
| July 6, 2023 |
Exhibit 10.3 EXECUTION VERSION CONSENT TO TERM LOAN AGREEMENT THIS CONSENT TO TERM LOAN AGREEMENT, dated as of July 3, 2023 (this “Consent”) is made among T2 BIOSYSTEMS, INC., a Delaware corporation (“Borrower”), the other Obligors party hereto, CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, “Administrative Agent”) and the lenders listed on the signature pages |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 30, 2023 |
US89853L2034 / T2 Biosystems Inc / GSA CAPITAL PARTNERS LLP Passive Investment Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) : T2 Biosystems Ord (Title of Class of Securities) : Common Stock (CUSIP Number) : 89853L2034 (Date of Event Which Requires Filing of this Statement) : 06/28/2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| June 23, 2023 |
US89853L2034 / T2 Biosystems Inc / Carrick Jason Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* T2 Biosystems, Inc. (Name of Issuer) Com New (Title of Class of Securities) 89853L203 (CUSIP Number) June 15, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| June 22, 2023 |
US89853L2034 / T2 Biosystems Inc / Markey John - 13G FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* T2 Biosystems, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 89853L203 (CUSIP Number) June 22, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| June 16, 2023 |
US89853L2034 / T2 Biosystems Inc / Markey John - 13G FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* T2 Biosystems, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 89853L203 (CUSIP Number) June 16, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| June 14, 2023 |
US89853L2034 / T2 Biosystems Inc / Markey John - 13G FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* T2 Biosystems, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 89853L203 (CUSIP Number) June 14, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| June 12, 2023 |
US89853L2034 / T2 Biosystems Inc / Markey John - 13G FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* T2 Biosystems, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 89853L203 (CUSIP Number) June 12, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 9, 2023 |
424B5 As Filed Pursuant to Rule 424(b)(5) Registration No. 333-254918 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated April 9, 2021, May 22, 2023, May 30, 2022 and June 5, 2023) and Prospectus dated April 9, 2021) Up to $8,871,000 Common Stock This Prospectus Supplement supplements the prospectus supplements, dated April 9, 2021, May 22, 2023, May 30, 2023 and June 5, 2023 (collectively, th |
|
| June 9, 2023 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical Use LEXINGTON, Mass., June 9, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced a collaborative relationship with |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 5, 2023 |
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel LEXINGTON, Mass., June 5, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and a |
|
| June 5, 2023 |
424B5 As Filed Pursuant to Rule 424(b)(5) Registration No. 333-254918 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated April 9, 2021, May 22, 2023 and May 30, 2022 and Prospectus dated April 9, 2021) Up to $5,392,000 Common Stock This Prospectus Supplement supplements the prospectus supplements, dated April 9, 2021, May 22, 2023 and May 30, 2023 (collectively, the “ATM Prospectus Supplement” |
|
| May 30, 2023 |
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History EX-99.1 2 d423227dex991.htm EX-99.1 Exhibit 99.1 T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the second largest sale of sepsis-driven T2Dx® Instruments in Company h |
|
| May 30, 2023 |
424B5 As Filed Pursuant to Rule 424(b)(5) Registration No. 333-254918 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated April 9, 2021 and May 22, 2023 and Prospectus dated April 9, 2021) Up to $2,824,000 Common Stock This Prospectus Supplement supplements the prospectus supplements, dated April 9, 2021 and May 22, 2023 (collectively, the “ATM Prospectus Supplement”), relating to the offer and |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 25, 2023 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces First Quarter 2023 Financial Results Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternatives LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance g |
|
| May 25, 2023 |
EX-99.2 Exhibit 99.2 T2 Biosystems 1Q May 23, 2023 Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products. Forward-looking statements are b |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 22, 2023 |
Exhibit 10.1 [****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 6 2. AMENDMENT/MODIFICATION NO. P00013 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE |
|
| May 22, 2023 |
Exhibit 10.2 WAIVER AND CONSENT THIS WAIVER AND CONSENT, dated as of May 19, 2023 (this “Waiver”), is made among T2 BIOSYSTEMS, INC., a Delaware corporation (“Borrower”), CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, “Administrative Agent”) and the lenders listed on the signature pages hereof under the heading “LENDERS” (each, a “Lender” and, collectively, th |
|
| May 22, 2023 |
424B5 As Filed Pursuant to Rule 424(b)(5) Registration No. 333-254918 PROSPECTUS SUPPLEMENT (To Prospectus and the Prospectus Supplement dated April 9, 2021) Up to $4,200,000 Common Stock This Prospectus Supplement supplements the prospectus supplement, dated April 9, 2021 (the “ATM Prospectus Supplement”), relating to the offer and sale of shares of our common stock, $0.001 par value per share, h |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Biosys |
|
| May 15, 2023 |
NT 10-Q SEC FILE NUMBER: 001-36571 CUSIP NUMBER: 89853L203 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read Instructions (on back page) Before Preparing Form. |
|
| March 31, 2023 |
Exhibit 10.56 Execution Version AMENDMENT No. 7 TO TERM LOAN AGREEMENT THIS AMENDMENT NO. 7 TO TERM LOAN AGREEMENT, dated as of February 15, 2022 (this “Amendment”) is made among T2 BIOSYSTEMS, INC., a Delaware corporation (“Borrower”), the other Obligors party hereto, CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, “Administrative Agent”) and the lenders liste |
|
| March 31, 2023 |
Exhibit 10.54 March 21, 2022 Michael Gibbs [*******] [*******] Dear Michael, This letter sets forth the agreement between you and T2 Biosystems, Inc. (the “Company”) regarding certain terms and conditions of your employment. This replaces any prior agreement between yourself and the Company with respect to the subject matter contained herein. You are entitled to receive the following: 1. Severance |
|
| March 31, 2023 |
Letter Agreement, dated March 30, 2023, by and between T2 Biosystems, Inc. and John Sprague Exhibit 10.67 March 30, 2023 John Sprague Re: Retention Bonus Dear John, T2 Biosystems, Inc. (the “Company” or “T2”) is pleased to inform you that you are eligible to earn a special, one-time retention bonus (the “Retention Bonus”) in the total aggregate amount of $80,000, to be paid in two installments of $40,000, pursuant to the terms and conditions set forth in this letter agreement. Subject to |
|
| March 31, 2023 |
Letter Agreement, dated March 30, 2023, by and between T2 Biosystems, Inc. and Brett Giffin EX-10 14 ttoo-ex1069.htm EX-10.69 Exhibit 10.69 March 30, 2023 Brett Giffin Re: Retention Bonus Dear Brett, T2 Biosystems, Inc. (the “Company” or “T2”) is pleased to inform you that you are eligible to earn a special, one-time retention bonus (the “Retention Bonus”) in the total aggregate amount of $80,000, to be paid in two installments of $40,000, pursuant to the terms and conditions set forth i |
|
| March 31, 2023 |
Exhibit 10.52 November 2, 2021 Brett Giffin [*******] [*******] Dear Brett: On behalf of T2 Biosystems, Inc., (the "Company") I am delighted to make this offer of employment to you to join us in the role of Chief Commercial Officer for the Company beginning on November 8, 2021. At T2 Biosystems, a leader in the detection of sepsis causing pathogens, our mission is to save lives and improve healthc |
|
| March 31, 2023 |
Exhibit 10.51 T2 BIOSYSTEMS, INC. INDUCEMENT AWARD PLAN (as amended and restated effective February 16, 2023) ARTICLE 1. PURPOSE The purpose of the T2 Biosystems, Inc. Inducement Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of T2 Biosystems, Inc. (the “Company”) by linking the individual interests of eligible individual |
|
| March 31, 2023 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT General As of December 31, 2022, T2 Biosystems, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). References herein to “we,” “us,” “our” and the “Company” refer to T2 Biosystems, Inc. and not to any of its subsidi |
|
| March 31, 2023 |
Exhibit 10.66 Execution Version WAIVER THIS WAIVER, dated as of January 23, 2023 (this “Waiver”) is made among T2 BIOSYSTEMS, INC., a Delaware corporation (“Borrower”), CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, “Administrative Agent”) and the lenders listed on the signature pages hereof under the heading “LENDERS” (each, a “Lender” and, collectively, the |
|
| March 31, 2023 |
Letter Agreement, dated March 30, 2023, by and between T2 Biosystems, Inc. and Michael Gibbs Exhibit 10.68 March 30, 2023 Michael Gibbs Re: Retention Bonus Dear Michael, T2 Biosystems, Inc. (the “Company” or “T2”) is pleased to inform you that you are eligible to earn a special, one-time retention bonus (the “Retention Bonus”) in the total aggregate amount of $80,000, to be paid in two installments of $40,000, pursuant to the terms and conditions set forth in this letter agreement. Subjec |
|
| March 31, 2023 |
Exhibit 10.53 March 21, 2022 John Sprague [*******] [*******] Dear John, This letter sets forth the agreement between you and T2 Biosystems, Inc. (the “Company”) regarding certain terms and conditions of your employment. This replaces any prior agreement between yourself and the Company with respect to the subject matter contained herein. You are entitled to receive the following: 1. Severance Com |
|
| March 31, 2023 |
Exhibit 10.65 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 7 2. AMENDMENT/MODIFICATION NO. P00012 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable) 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDA ASPR-BARDA ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20 |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36571 T2 Biosystems, Inc. (Exa |
|
| March 31, 2023 |
Exhibit 10.64 AMENDMENT NO. 6 TO COMMERCIAL LEASE BETWEEN COLUMBUS DAY REALTY, INC. AND T2 BIOSYSTEMS, INC. This Amendment No. 6 is to a Commercial Lease dated May 6, 2013, by and between Columbus Day Realty, Inc. (LESSOR), and T2 Biosystems, Inc. (LESSEE), which lease relates to the premises at 231 Andover Street, Wilmington, Massachusetts. WHEREAS, the Commercial Lease is dated May 6, 2013; WHER |
|
| March 31, 2023 |
Exhibit 10.55 March 21, 2022 Brett Giffin [*******] [*******] Dear Brett, This letter sets forth the agreement between you and T2 Biosystems, Inc. (the “Company”) regarding certain terms and conditions of your employment. This replaces any prior agreement between yourself and the Company with respect to the subject matter contained herein. You are entitled to receive the following: 1. Severance Co |
|
| March 31, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of T2 Biosystems, Inc.: Name Jurisdiction of Organization T2 Biosystems Securities Corporation Massachusetts |
|
| March 16, 2023 |
EX-99.2 Exhibit 99.2 T2 Biosystems 4Q March 13, 2023 Regan Talley, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products. Forward-looking statements ar |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File |
|
| March 16, 2023 |
EX-99.1 2 d487064dex991.htm EX-99.1 Exhibit 99.1 T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument placements in 2022 LEXINGTON, Mass., March 13, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resista |
|
| February 21, 2023 |
US89853L2034 / T2 Biosystems Inc / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* T2 Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89853L203 (CUSIP Number) February 17, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 21, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of T2 Biosystems, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Sch |
|
| February 16, 2023 |
EX-1.1 Exhibit 1.1 9,018,519 SHARES OF COMMON STOCK 22,222,222 COMMON WARRANTS (EXERCISABLE FOR 22,222,222 WARRANT SHARES) AND 2,092,592 PRE-FUNDED WARRANTS (EXERCISABLE FOR 2,092,592 WARRANT SHARES) T2 BIOSYSTEMS, INC. UNDERWRITING AGREEMENT February 14, 2023 Craig-Hallum Capital Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 222 South Ninth Street |
|
| February 16, 2023 |
EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT T2 BIOSYSTEMS, INC. Warrant Shares: Initial Exercise Date: February 17, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| February 16, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254918 PROSPECTUS SUPPLEMENT (To Prospectus dated April 9, 2021) 9,018,519 Shares of Common Stock Warrants to Purchase up to 22,222,222 Shares of Common Stock Pre-funded Warrants to Purchase up to 2,092,592 Shares of Common Stock We are offering 9,018,519 shares of common stock, pre-funded warrants to purchase 2,092,592 |
|
| February 16, 2023 |
EX-4.2 4 d426940dex42.htm EX-4.2 Exhibit 4.2 COMMON STOCK PURCHASE WARRANT T2 BIOSYSTEMS, INC. Warrant Shares: Initial Exercise Date: February 17, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| February 13, 2023 |
Subject to Completion, Dated February 13, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254918 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sel |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| January 23, 2023 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022 LEXINGTON, Mass., January 23, 2023 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced prelimin |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 25, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| November 14, 2022 |
Exhibit 10.5 AMENDMENT No. 8 TO TERM LOAN AGREEMENT THIS AMENDMENT NO. 8 TO TERM LOAN AGREEMENT, dated as of November 10, 2022 (this ?Amendment?) is made among T2 BIOSYSTEMS, INC., a Delaware corporation (?Borrower?), the other Obligors party hereto, CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, ?Administrative Agent?) and the lenders listed on the signature |
|
| November 14, 2022 |
EXHIBIT 10.4 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGE 1 ? 53 2. AMENDMENT/MODIFICATION NO. P000l0 3. EFFECTIVE DATE See Block 16C 6. ISSUED BY CODE ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 [****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not mater |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Bi |
|
| November 10, 2022 |
Exhibit 99.1 T2 Biosystems Announces Third Quarter 2022 Financial Results Achieves record quarterly sepsis and related revenue and advances product pipeline LEXINGTON, Mass., November 10, 2022 (GLOBE NEWSWIRE)?T2 Biosystems, Inc. (NASDAQ:TTOO) (the ?Company?), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the thir |
|
| November 10, 2022 |
Exhibit 99.2 T2 Biosystems 3Q November 10, 2022 Philip Taylor Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems? future financial and operating results and plans for developing and marketing new products. Forward-looking statements are based |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission F |
|
| November 7, 2022 |
HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize EX-99.1 Exhibit 99.1 HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize LEXINGTON, Mass., November 7, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra C |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 14, 2022 |
EX-99.1 Exhibit 99.1 T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations Studies demonstrate that T2Bacteria and T2Candida panels enable sensitive and specific diagnosis to enhance the standard of care LEXINGTON, Mass., October 14, 2022 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-c |
|
| October 13, 2022 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease Plans to Initiate Marketing and Sales in the U.S. as a Laboratory Developed Test in 2023 LEXINGTON, Mass., October 13, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today plans |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 12, 2022 |
T2 Biosystems Announces Reverse Stock Split Effective Today EX-99.2 Exhibit 99.2 T2 Biosystems Announces Reverse Stock Split Effective Today TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2022 LEXINGTON, Mass., October 12, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Compan |
|
| October 12, 2022 |
EX-99.1 Exhibit 99.1 T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook LEXINGTON, Mass., October 12, 2022 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the third quart |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2022 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 12, 2022 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF T2 BIOSYSTEMS, INC. T2 Biosystems, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: That, the Board of Directors of the Company duly adopted resolutions by unanimous written consent in a |
|
| September 30, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commi |
|
| September 30, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 24, 2022 (Date of earliest event reported) T2 Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 26, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| August 17, 2022 |
Exhibit 99.2 T2 Biosystems 2Q August 15, 2022 Emma Poalillo Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems? future financial and operating results and plans for developing and marketing new products. Forward-looking statements are based on |
|
| August 17, 2022 |
Exhibit 99.1 T2 Biosystems Announces Second Quarter 2022 Financial Results T2Dx Instrument contracts increased by 300% compared to the prior year period LEXINGTON, Mass., August 15, 2022 (GLOBE NEWSWIRE)?T2 Biosystems, Inc. (NASDAQ:TTOO) (the ?Company?), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the second qua |
|
| August 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission Fil |
